Renal function and severity of bright liver. Relationship with insulin resistance, intrarenal resistive index, and glomerular filtration rate

Hepatology International

Volumn 5, Issue 3, 2011, Pages 822-829

  Catalano, Daniela ^a   Trovato, Guglielmo M ^a   Martines, Giuseppe Fabio ^a   Pirri, Clara ^a   Trovato, Francesca M ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Bright liver; Glomerular filtration rate; Insulin resistance; NAFLD; Obesity; Renal resistive index

Indexed keywords

AMINOTRANSFERASE; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADULT; ARTICLE; BODY MASS; BRIGHT LIVER; BRIGHT LIVER SCORE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ECHOGRAPHY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INTERMETHOD COMPARISON; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MEDITERRANEAN DIET; NONALCOHOLIC FATTY LIVER; NUTRITIONAL COUNSELING; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; SMOKING CESSATION; WAIST HIP RATIO;

EID: 80055004073     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-011-9254-2     Document Type: Article

References (42)

1. Ginès P, Schrier RW. Renal failure in cirrhosis. N Engl J Med 2009;361:1279-1290
2. Chang Y, Ryu S, Sung E, Woo HY, Oh E, Cha K, et al. Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men. Metabolism. 2008;57:569-576 (Pubitemid 351320606)
3. Targher G, Bertolini L, Rodella S, Zoppini G, Lippi G, Day C, et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia. 2008;51:444-450
4. Syn WK, Nightingale P, Bateman JM. Nonalcoholic fatty liver disease in a district general hospital: clinical presentation and risk factors. Hepatol Int 2008;2:190-195 (Pubitemid 351650147)
5. Ichikawa T, Nakao K, Hamasaki K, Furukawa R, Tsuruta S, Ueda Y, et al. Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease. Hepatol Int 2007;1:287-294
6. Lemoine M, Ratziu V, Kim M, Maachi M, Wendum D, Paye F, et al. Serum adipokine levels predictive of liver injury in nonalcoholic fatty liver disease. Liver Int 2009;29:1431-1438
7. Arrese M, Riquelme A. The value of serum adipokine measurement in non-alcoholic fatty liver disease. Liver Int 2009;29:1291-1293
8. Goessling W, Massaro JM, Vasan RS, D'Agostino RB Sr, Ellison RC, Fox CS. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology. 2008;135:1935-1944
9. Riquelme A, Arrese M, Soza A, Morales A, Baudrand R, Pèrez-Ayuso RM, et al. Non-alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics. Liver Int 2009;29:82-88
10. Mathiesen UL, Franzèn LE, Aselius H, Resjö M, Jacobsson L, Foberg U, et al. Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases. Dig Liver Dis 2002;34:516-522 (Pubitemid 34830694)
11. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128:1898-1906 (Pubitemid 40824701)
12. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123:745-750 (Pubitemid 34977081)
13. Rosenberg DE, Jabbour SA, Goldstein BJ. Insulin resistance, diabetes and cardiovascular risk: approaches to treatment. Diabetes Obes Metab 2005;7:642-653 (Pubitemid 41601069)
14. Daniels SR, Arnett DK, Eckel RH, Gidding SS, Hayman LL, Kumanyika S, et al. Overweight in children and adolescents: pathophysiology, consequences, prevention, and treatment. Circulation. 2005;111:1999-2012 (Pubitemid 40570221)
15. Ghandehari H, Le V, Kamal-Bahl S, Bassin SL, Wong ND. Abdominal obesity and the spectrum of global cardiometabolic risks in US adults. Int J Obes (Lond) 2009;33:239-248
16. Chagnac A, Herman M, Zingerman B, Erman A, Rozen-Zvi B, Hirsh J, et al. Obesity-induced glomerular hyperfiltration: its involvement in the pathogenesis of tubular sodium reabsorption. Nephrol Dial Transplant 2008;23:3946-3952
17. Krikken JA, Bakker SJ, Navis GJ. Role of renal haemodynamics in the renal risks of overweight. Nephrol Dial Transplant 2009;24:1708-1711
18. Bosma RJ, van der Heide JJ, Oosterop EJ, de Jong PE, Navis G. Body mass index is associated with altered renal hemodynamics in non-obese healthy subjects. Kidney Int 2004;65:259-265 (Pubitemid 38037512)
19. Ribstein J, du Cailar G, Mimran A. Combined renal effects of overweight and hypertension. Hypertension. 1995;26:610-615
20. Chagnac A, Weinstein T, Korzets A, Ramadan E, Hirsch J, Gafter U. Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol 2000;278:F817-822 (Pubitemid 30351084)
21. Chagnac A, Weinstein T, Herman M, Hirsh J, Gafter U, Ori Y. The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 2003;14:1480-1486 (Pubitemid 36687049)
22. Praga M. Synergy of low nephron number and obesity: a new focus on hyperfiltration nephropathy. Nephrol Dial Transplant 2005;20:2594-2597 (Pubitemid 41672251)
23. Pecly IM, Genelhu V, Francischetti EA. Renal functional reserve in obesity hypertension. Int J Clin Pract 2006;60:1198-1203 (Pubitemid 44375440)
24. Ohta Y, Fujii K, Arima H, Matsumura K, Tsuchihashi T, Tokumoto M, et al. Increased renal resistive index in atherosclerosis and diabetic nephropathy assessed by Doppler sonography. J Hypertens 2005;23:1905-1911 (Pubitemid 41830431)
25. Sugiura T, Wada A. Resistive index predicts renal prognosis in chronic kidney disease. Nephrol Dial Transplant 2009;24:2780-2785
26. Pontremoli R, Viazzi F, Martinoli C, Ravera M, Nicolella C, Berruti V, et al. Increased renal resistive index in patients with essential hypertension: a marker of target organ damage. Nephrol Dial Transplant 1999;14:360-365 (Pubitemid 29062791)
27. Trovato GM, Catalano D, Sciacchitano G, Zuccalà G, Iannetti E. Resistive index of renal artery and blood pressure in postmenopausal women. Maturitas. 2002;25(41):223-230 (Pubitemid 34211977)
28. Hamano K, Nitta A, Ohtake T, Kobayashi S. Associations of renal vascular resistance with albuminuria and other macroangiopathy in type 2 diabetic patients. Diabetes Care. 2008;31:1853-1857
29. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1-10
30. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419 (Pubitemid 15018832)
31. Rutter MK, Wilson PW, Sullivan LM, Fox CS, D'Agostino RB Sr, Meigs JB. Use of alternative thresholds defining insulin resistance to predict incident type 2 diabetes mellitus and cardiovascular disease. Circulation. 2008;117:1003-1009
32. Catalano D, Trovato GM, Martines GF, Randazzo M, Tonzuso A. Bright liver, body composition and insulin resistance changes with nutritional intervention: a follow-up study. Liver Int 2008;28:1280-1287
33. Keogan M, Kliewer M, Hertzberg B, DeLong DM, Tupler RH, Carroll BA. Renal resistive indexes: variability in Doppler US measurement in a healthy population. Radiology. 1996;199:165-169 (Pubitemid 26095832)
34. KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007;49(2 Suppl 2):S12-154
35. Premaratne E, Macisaac RJ, Tsalamandris C, Panagiotopoulos S, Smith T, Jerums G. Renal hyperfiltration in type 2 diabetes: effect of age-related decline in glomerular filtration rate. Diabetologia. 2005;48:2486-2493 (Pubitemid 41738212)
36. Møller S, Henriksen JH, Bendtsen F. Pathogenetic background for treatment of ascites and hepatorenal syndrome. Hepatol Int 2008;2:416-428
37. Kumar A, Das K, Sharma P, Mehta V, Sharma BC, Sarin SK. Hemodynamic studies in acute-on-chronic liver failure. Dig Dis Sci 2009;54:869-878
38. Hoffler U, Hobbie K, Wilson R, Bai R, Rahman A, Malarkey D, et al. Diet-induced obesity is associated with hyperleptinemia, hyperinsulinemia, hepatic steatosis, and glomerulopathy in C57Bl/6 J mice. Endocrine. 2009;36:311-325
39. Nanayakkara PW, Le Poole CY, Fouque D, van Guldener C, Stehouwer CD, Smulders YM, et al. Plasma adiponectin concentration has an inverse and a non linear association with estimated glomerular filtration rate in patients with K/DOQI 3-5 chronic kidney disease. Clin Nephrol 2009;72:21-30
40. Sell H, Dietze-Schroeder D, Eckel J. The adipocyte-myocyte axis in insulin resistance. Trends Endocrinol Metab 2006;17:416-422 (Pubitemid 44780130)
41. Malhi H, Gores GJ. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis 2008;28:360-369
42. Ohki T, Tateishi R, Shiina S, Goto E, Sato T, Nakagawa H, et al. Visceral fat accumulation is an independent risk factor for hepatocellular carcinoma recurrence after curative treatment in patients with suspected NASH. Gut. 2009;58:839-844